| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000041108 |
| Receipt No. | R000046947 |
| Scientific Title | Validation study on the effects on liver function and skin barrier function by intake of adlay |
| Date of disclosure of the study information | 2020/07/15 |
| Last modified on | 2021/01/13 (Ver. 3) |
| Basic information | ||
| Public title | Validation study on the effects on liver function and skin barrier function by intake of adlay | |
| Acronym | Validation study on the effects on liver function and skin barrier function by intake of adlay | |
| Scientific Title | Validation study on the effects on liver function and skin barrier function by intake of adlay | |
| Scientific Title:Acronym | Validation study on the effects on liver function and skin barrier function by intake of adlay | |
| Region |
|
|
| Condition | ||
| Condition | Healthy Adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluate the effects of liver function and skin barrier function by adlay tea intake for 8 weeks. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | -liver function (AST, ALT, gamma-GTP )
-skin hydration (Transepidermal water loss, Moisture) At the beginning of the test or after the intake for 8 weeks. |
| Key secondary outcomes | -Blood test (total protein, albumin, ,blood neutral fat (TG), total cholesterol, HDL-cholesterol, LDL-cholesterol, urea nitrogen , ALP, CPK, total bilirubin, uric acid, urea nitrogen, creatinine, sodium, potassium, chlorine, calcium, phosphorus, magnesium, LDH, white blood cell count, red blood cell count, hemoglobin, hematocrit, platelet count, MCV, MCH, MCHC)
-Physical examination (body height, weight, BMI, blood pressure, pulse) -Food questionnaire |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake 500mL of adlay tea daily for 8 weeks. | |
| Interventions/Control_2 | Intake 500ml of barley tea daily for 8 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document
2.Japanese women who are 20 years old or more and under 65 years old 3.Persons who are the bottom 70 of the value of skin hydration at screening |
|||
| Key exclusion criteria | 1.Persons who have chronic illness, receiving medication, have a serious disease history
2.Persons who are allergic to the test food 3.Persons who usually take a large amount of test food 4.Persons whose ALT or AST is over 51 U/L at screening 5.Persons whose gamma-GTP is over 101 U/L at screening 6.Persons whose habitually consume higher amount of alcohol (>60g alcohol/day) 7.Persons who have skin disease such as atopic dermatitis, urticaria, eczema and dermatitis. 8.Persons who regularly use medicines, specified insurance foods, health foods, etc. that may affect liver function and skin function 9.Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam 10.Persons who are pregnant, planning or hoping to be pregnant during the study period, breastfeeding 11.Persons who were judged as inappropriate for subjects by the principal investigator |
|||
| Target sample size | 70 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Healthcare Systems Co., Ltd. | ||||||
| Division name | Research and Development Department | ||||||
| Zip code | 105-0004 | ||||||
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN | ||||||
| TEL | 03-6809-2722 | ||||||
| ishikawa@hc-sys.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Healthcare Systems Co., Ltd. | ||||||
| Division name | Research and Development Department | ||||||
| Zip code | 105-0004 | ||||||
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN | ||||||
| TEL | 03-6809-2722 | ||||||
| Homepage URL | |||||||
| izumi@hc-sys.jp | |||||||
| Sponsor | |
| Institute | Healthcare Systems Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Cabinet Office |
| Organization | |
| Division | |
| Category of Funding Organization | Government offices of other countries |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Oyama city |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The Ethics Committee of Healthcare Systems Co., Ltd. |
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN |
| Tel | 03-6809-2722 |
| soumu@hc-sys.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 70 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046947 |